Janssen: New pan-European survey reveals that only 14% of healthcare professionals feel sufficiently equipped to address prostate cancer patients’ quality of life issues
15.9.2015 22:01 | Business Wire
A new report released today entitled Prostate Cancer: Living, not Just Surviving , which details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals, reveals that only 14 per cent of healthcare professionals feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems. 1
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150915006448/en/
Developed by Janssen in collaboration with pan-European and national patient associations, the survey reveals that for the patients who experience chronic physical effects from the disease, fatigue (66%) has the biggest negative impact compared to disability and pain (41% and 22% respectively), particularly in metastatic patients (93%) and patients on medication (83%). Almost half of all men with prostate cancer surveyed (n=765) state that they are so tired, they no longer feel able to exercise and 74 per cent of this group say that this has had a negative effect on them emotionally.
It also suggests that men with prostate cancer worry more about quality of life issues associated with their disease, such as intimacy problems (54%) and feeling ill (41%), than dying (36%).
Professor Louis Denis, Onco-Urologist and Strategic Consultant, Europa Uomo said: “Prostate cancer is increasingly considered to be a chronic illness, as many men with the disease are now living longer. This opens up a new challenge for healthcare professionals, and the patients themselves, to place just as much focus on managing quality of life issues as they do on addressing survival.”
“Patient advocacy groups, such as Europa Uomo, can play an important role in supporting prostate cancer patients who are struggling emotionally and physically with their disease by providing the right up-to-date information on managing quality of life issues. They can also act as an avenue for patients and caregivers to connect and share their experiences with others who are living with the disease.”
The report reveals that almost all healthcare professionals (92%) surveyed believe that they proactively provide advice to patients on ways to improve their physical and emotional wellbeing. Conversely, only 14% of patients can recall their doctor advising them on ways to improve their physical and emotional well-being, aside from using medication.1
Dr Maria De Santis, Cancer Research Unit, University of Warwick, UK, said: “Communication is key. We hope that by having a greater understanding of the everyday individual experiences of patients and their caregivers, we as healthcare professionals, may be able to tailor the way we manage the disease to provide a more personalised and holistic approach to care.”
She continued: “Managing quality of life is extremely important in the overall process of caring for a patient with prostate cancer. However, many different methods of measuring quality of life exist, and healthcare professionals may not always be trained in or even aware of these methods. Healthcare professionals may therefore benefit from a single, simple, internationally-recognised quality of life measure to provide a consistent way to identify each patient’s needs.”
Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA), said: “At Janssen we know that effective prostate cancer management goes beyond the provision of life-prolonging medicines. As prostate cancer is increasingly becoming a long-term and chronic disease, it is important that we work together to support men and their families to manage the quality of life issues related to the disease.”
“We hope that by shedding light on the experiences of patients, caregivers and healthcare professionals in Europe, this report will improve our understanding of how emotional, social issues and physical problems related to prostate cancer can be more effectively addressed through tailored personalised care.”
Latest prostate cancer figures show that there are currently three million men living with the disease in Europe2 and that the number is continuing to rise, with an increase of over 150% across more than a decade (1999 – 2012).3,4 Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe per year.3
The pan-European survey was carried out in ten countries across Europe by the independent research company, InSites Consulting. The Prostate Cancer: Living, not Just Surviving report can be viewed online at: http://www.janssen-emea.com/hpc/reports/Living-prostate-cancer
NOTES TO EDITORS
About the Prostate Cancer: Living not Surviving survey
The Prostate Cancer: Living, not Just Surviving survey was initiated on the recommendation of an independent European patient advocacy group panel, which identified a need to improve support for men with prostate cancer by focusing on the longer-term, holistic (quality of life) needs of them and their caregivers.
A pan-European survey was then carried out amongst 765 patients, 335 caregivers and 400 healthcare professionals to ascertain their views on the physical and emotional impact of prostate cancer. The survey was undertaken by the independent research company, InSites Consulting.
Participants were recruited from online research panels and through patient association group partners. Patients and caregivers were sourced from ten countries across Europe, including: the UK, Finland, France, Germany, Italy, Norway, Spain, Sweden, The Netherlands and Belgium. Healthcare professionals were surveyed in the UK, France, Germany, Spain and Italy.
The survey was developed and implemented in partnership with the following expert patient advocacy group panel members:
- Professor Louis Denis – Europa Uomo (EU)
- Christian Arnold – Association Nationale des Malades du Cancer de la Prostate (ANAMACAP) (FR)
- David Smith and Hugh Gunn – Prostate Cancer Support Federation (Tackle Prostate Cancer) (UK)
- Ian Banks – European Men’s Health Forum (EMHF) (EU)
- Calle Waller – Prostatacancerförbundet (SWE)
About European Prostate Cancer Awareness Day (EPAD)
EPAD 2015 is taking place in the European Parliament in Brussels on 16th September 2015, hosted and chaired by Mr P. De Backer MEP and co-chaired by Prof. C. Chapple, Secretary General of the European Association of Urology and Mr K. Mastris, Chairman of Europa Uomo.
EPAD 2015 aims to raise awareness, understanding and knowledge of the management of prostate diseases in general and prostate cancer in particular, and to highlight their significant impact on men across Europe and the burden on European social health care.
The event brings together key policy makers, scientific experts and European associations working in the urological field and representatives of European patient groups with an interest in prostate disease. During this event several experts will discuss the impact of living with benign prostatic enlargement and prostate cancer and how we can improve care and empower patients in the future.
About Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic castration-resistant prostate cancer occurs when cancer has metastasised (spread) beyond the prostate to other parts of the body and the disease progresses despite serum testosterone below castrate levels.5
The prostate is a gland in men that produces part of the seminal fluid and is located around the urethra (under the bladder). In some cases, cancer of the prostate can grow slowly. However, depending on factors including characteristics specific to the patient and the tumour, prostate cancer also can grow very quickly and spread widely.6
In 2012, over 400,000 new cases of prostate cancer were diagnosed in Europe, and nearly 92,000 men died from the disease.3
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including in oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare professionals, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
About Janssen in Oncology
In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include disease area strongholds that focus on haematologic malignancies and prostate cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.
# # #
1 ‘Prostate Cancer: Living not just surviving’ report. Available at: http://www.janssen-emea.com/hpc/reports/Living-prostate-cancer
2 European Commission. CORDIS Express: Prevention, diagnosis and treatment of prostate cancer. Available at: http://cordis.europa.eu/news/rcn/122705_en.html. Last accessed August 2015.
3 Ferlay J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Can. 2013;49:1374– 1403.
4 Sant M et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J of Can. 2009;45:931991.
5 Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010 September; 17 (Supplement 2): S72–S79.
6 Mayo Clinic. Prostate Cancer. Available at: http://www.mayoclinic.com/health/prostate-cancer/DS00043. Last accessed August 2015.
+44 (0)1494 567602
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IBC’s Big Screen to Explore the Future of Camera and Display Technologies and the Business Behind Cinema22.8.2017 16:58 | Pressemelding
IBC today announced the details of its Big Screen programme, taking place in a specially built auditorium designed to IBC’s specifications and featuring the very latest in cinema technology. With the latest Dolby Vision dramatic imaging and Dolby Atmos immersive audio sound installation, the four-day programme examines and demonstrates the hottest topics, themes, and insights surrounding the art, science, and business of cinema - from capture through to exhibition. As well as being the home of the Big Screen programme, the auditorium will screen in Dolby Vision and Dolby Atmos, Baby Driver, the acclaimed Edgar Wright feature from 2017. The programme for 2017, which has been shaped by a committee of global industry professionals, is an insightful examination of the future of cinema. From virtual reality in cinema to laser and camera assessments, visitors will get up to speed
Digi Communications N.V. Announces the Publishing of an Update to the Investigation by the Romanian National Anti-Corruption Directorate22.8.2017 16:38 | Pressemelding
In connection with the investigation triggered by the Romanian National Anti-Corruption Directorate (“DNA”), which we have previously disclosed to the market and to our investors in the initial public offering prospectus dated 26 April 2017, in the supplemental prospectus dated 8 May 2017 (together, the “Prospectus”), as well as in the subsequent public reports, we inform you that, based on the public release no 832/VIII/3 issued on 22 August 2017, the DNA sent to court under the judiciary control Mr. Ioan Bendei (Vice-president of the Board of Directors of RCS & RDS S.A. – the Company’s subsidiary („RCS&RDS”)) in connection with the offences of bribery and accessory to money laundering, as well as RCS&RDS in connection with the offences of bribery and money laundering, INTEGRASOFT S.R.L. (one of RCS&RDS’s subsidiaries in Romania) in connection with the offence of accessory to mon
SailPoint Named a Leader in Cloud-based Identity Governance22.8.2017 14:00 | Pressemelding
SailPoint, the leader in enterprise identity management, was recently named the overall market leader in KuppingerCole’s 2017 “Leadership Compass: Identity as a Service: Cloud-based Provisioning, Access Governance and Federation.” In addition to being named a leader in every category of the report, SailPoint received superior rankings in four of the five evaluation criteria: security, functionality, interoperability and usability. KuppingerCole is an international and independent analyst organization with a strong focus on Information Security and Identity and Access Management. KuppingerCole’s Leadership Compass reports provide an in-depth analysis of the main players in the market, defining each as a follower, challenger or leader. The Leadership Compass Report for IDaaS evaluates leaders in innovation, product features, and market reach for identity-as-a-service offerings tar
Meggitt Training Systems to Exhibit at DSEI 201722.8.2017 14:00 | Pressemelding
Meggitt Training Systems, the leading provider of integrated live-fire and virtual weapons training products and services for armed forces and law enforcement, will participate at Defence and Security Equipment International (DSEI) through the Georgia Department of Economic Development. The military and security industry event will be held September 12-15, 2017 at ExCeL in London, England. “Today’s threats necessitate maximum realism, despite stretched budgets, and that’s what Meggitt provides to government and commercial customers globally,” said Mark Mears, managing director at Meggitt Training Systems, Ltd. “Although proudly based in Georgia, Meggitt Training Systems is part of Meggitt PLC, a UK-headquartered corporation. As such, we particularly look forward to engaging with current and prospective customers at DSEI, the UK’s largest defense and security trade show.” On
Camelbay Real Estate Management NL B.V. Selects Yardi Voyager22.8.2017 13:58 | Pressemelding
Camelbay Real Estate Management NL B.V. will utilise Yardi Voyager® 7S, a browser-agnostic, fully mobile Software-as-a-Service platform, as its accounting and property management platform. Camelbay will use Yardi Voyager to streamline its property management, leasing and accounting processes for its Dutch real estate portfolio, which is predominantly comprised of commercial office assets. “The automation, transparency and fully integrated accounting and property management that Voyager provides will help us manage our daily financial and operational activities more efficiently and enhance our competitive position within the Dutch office market,” said Alon Levy, Director of Camelbay Real Estate Management NL B.V. “We are very pleased to welcome Camelbay as our latest client in the Netherlands,” said Neal Gemassmer, Vice President of International for Yardi.
Laser Design CyberGage®360, Automated 3D Scanning & Inspection System Adopted by Proto Labs in their State-of-the-Art Metrology Lab22.8.2017 13:44 | Pressemelding
Laser Design, Inc., a subsidiary of CyberOptics (NASDAQ:CYBE), and premier provider of ultra-precise 3D scanning systems and services, announces the adoption of the CyberGage360 3D Scanning and Inspection system by Proto Labs, the world’s fastest digital manufacturing source for custom prototypes and low-volume production parts providing unprecedented speed-to-market value for designers and engineers. “At Proto Labs, we strive to challenge the traditional rules of manufacturing in order to deliver custom manufactured components at unprecedented speeds,” said Dylan Lundberg, Senior Manufacturing Engineer of Protoworks, Proto Labs’ R&D lab. “Everything we do revolves around reducing our customers’ time to market and we do that by digitalizing the entire manufacturing process. From our front-end services to our proprietary processes on the manufacturing floor, you will find thr
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom